Results 41 to 50 of about 926 (182)

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies. [PDF]

Int J Hepatol
Metabolic‐associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated.
Cooper J, Patel P, Tristeza J, Yang A.
europepmc   +2 more sources

Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

National Journal of Physiology, Pharmacy and Pharmacology, 2021
Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit.
Vidhya Sreekumar, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, Jyotirmoyee Jena   +5 more
doaj   +1 more source

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH. [PDF]

J Clin Exp Hepatol
Tavaglione F, Loomba R.
europepmc   +3 more sources

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

Biomolecules, 2023
The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment.
Shotaro Kamata, Akihiro Honda, Isao Ishii   +2 more
doaj   +1 more source

Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Nephropathy is the most common comorbidity linked to T2D. The present study aimed to examine the potential of saroglitazar in the context of a high-fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Rizwan Ahamad, Uma Bhandari, Sayima Nabi, Shweta Sharma   +3 more
doaj   +1 more source

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Cardiovascular Diabetology, 2020
Background The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention.
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar   +9 more
doaj   +1 more source

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD : A Randomized Controlled Double‐Blind Phase 2 Trial

, 2021
Background and Aims Non-alcoholic fatty liver disease (NAFLD) is characterized by insulin resistance and dysregulated lipid and glucose metabolism.
Lai, Michelle, Schiff, Eugene, Gawrieh, Samer, Cusi, Kenneth, Kowdley, Kris V., Noureddin, Mazen, Loo, Nicole, Kowdley, Kris V, Chalasani, Naga, Mohseni, Rizwana, Parmar, Deven, Patel, Pankaj, Awasty, Vivek   +12 more
core   +1 more source

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

, 2022
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual agonistic properties (α/γ). Due to a strong mechanistic rationale, we aimed to test the safety and efficacy of saroglitazar in patients with primary biliary ...
Pyrsopoulos, Nikolaos, Parmar, Deven V, Levy, Cynthia, Rossi, Simona, Chalasani, Naga P, Caldwell, Stephen H, Vuppalanchi, Raj, Shaikh, Farheen, Goldberg, David S, Bainbridge, James D, deLemos, Andrew S, Sheikh, Aasim, Mena, Edward A, Ravinuthala, Ravi   +13 more
core   +1 more source

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Non-alcoholic fatty liver disease (NAFLD) is a chronic steatohepatitis disorder. If left untreated, it can progress to hepatocellular carcinoma.
Reza Afarin, Negar Dinarvand, Hossein Azizi Dariuni, Ghazal Orak, Bahar Jaberian Asl, Reza Azizi, Azam Khedri   +6 more
doaj   +1 more source